DK0666760T4 - Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktioner - Google Patents
Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktionerInfo
- Publication number
- DK0666760T4 DK0666760T4 DK92920757T DK92920757T DK0666760T4 DK 0666760 T4 DK0666760 T4 DK 0666760T4 DK 92920757 T DK92920757 T DK 92920757T DK 92920757 T DK92920757 T DK 92920757T DK 0666760 T4 DK0666760 T4 DK 0666760T4
- Authority
- DK
- Denmark
- Prior art keywords
- ige
- vaccine
- pct
- mediated
- antibodies
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 5
- 230000001404 mediated effect Effects 0.000 title abstract 5
- 230000007815 allergy Effects 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 210000003912 basophilic leucocyte Anatomy 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9102808A SE9102808L (sv) | 1991-09-26 | 1991-09-26 | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
PCT/SE1992/000673 WO1993005810A1 (en) | 1991-09-26 | 1992-09-25 | VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
DK0666760T3 DK0666760T3 (da) | 2000-07-31 |
DK0666760T4 true DK0666760T4 (da) | 2008-01-21 |
Family
ID=20383848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92920757T DK0666760T4 (da) | 1991-09-26 | 1992-09-25 | Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktioner |
Country Status (16)
Country | Link |
---|---|
US (1) | US5653980A (da) |
EP (1) | EP0666760B2 (da) |
JP (2) | JP3583421B2 (da) |
KR (1) | KR100263359B1 (da) |
AT (1) | ATE189960T1 (da) |
AU (1) | AU677573B2 (da) |
CA (1) | CA2117193C (da) |
DE (1) | DE69230733T3 (da) |
DK (1) | DK0666760T4 (da) |
ES (1) | ES2144424T5 (da) |
FI (1) | FI107880B (da) |
GR (1) | GR3033272T3 (da) |
HU (1) | HU218899B (da) |
RU (1) | RU2120805C1 (da) |
SE (1) | SE9102808L (da) |
WO (1) | WO1993005810A1 (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
AU707083B2 (en) * | 1993-08-26 | 1999-07-01 | Bavarian Nordic Inc. | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes |
JP3825798B2 (ja) * | 1994-01-18 | 2006-09-27 | ジェネンテク,インコーポレイテッド | IgEアンタゴニストを用いる寄生虫感染症の治療法 |
FR2715304B1 (fr) * | 1994-01-26 | 1996-04-26 | Merieux Serums Vaccins Pasteur | Vaccin anti-allergique. |
HUP9901109A3 (en) * | 1996-03-01 | 1999-11-29 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
PL194221B1 (pl) * | 1997-04-15 | 2007-05-31 | Pharmexa As | Zmodyfikowana cząsteczka ludzkiego TNFalfa, dimery, oligomery lub multimery zmodyfikowanej cząsteczki ludzkiego TNFalfa, wyizolowana cząsteczka DNA, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania zmodyfikowanej cząsteczki ludzkiego TNFalfa, szczepionki przeciwko TNFalfa oraz zastosowanie przynajmniej jednej zmodyfikowanej cząsteczki ludzkiego TNFalfa |
US7393529B2 (en) | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
US6504013B1 (en) | 2000-02-01 | 2003-01-07 | Idexx Laboratories, Inc. | Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody |
US6734287B1 (en) | 1998-04-09 | 2004-05-11 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
EP1621209A3 (en) * | 1998-11-02 | 2006-04-19 | Resistentia Pharmaceuticals AB | Vaccines based on domains of chimeric immunoglobulin E peptides |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
US6602719B1 (en) | 1999-03-26 | 2003-08-05 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
US6511814B1 (en) | 1999-03-26 | 2003-01-28 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
US6887472B2 (en) | 2000-08-30 | 2005-05-03 | Pfizer Inc. | Anti-IgE vaccines |
JP2003047482A (ja) * | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | 非アナフィラキシー誘発性IgEワクチン |
EP1497654A4 (en) * | 2001-08-13 | 2006-06-07 | Chen Swey Shen Alex | IMMUNOGLOBULIN E VACCINES AND METHODS OF USE |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
EP1545607B1 (en) * | 2002-09-05 | 2008-11-19 | Resistentia Pharmaceuticals AB | Allergy vaccines |
US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
HUE030269T2 (en) | 2006-06-26 | 2017-04-28 | Macrogenics Inc | FC RIIB-specific antibodies and methods for their use |
US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
EP2865389A1 (en) | 2008-12-09 | 2015-04-29 | Pfizer Vaccines LLC | IgE CH3 peptide vaccine |
SG174161A1 (en) * | 2009-02-25 | 2011-11-28 | Tsewen Chang | ANTI-CemX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES |
EP2942061A3 (en) * | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
US9587034B2 (en) | 2012-04-20 | 2017-03-07 | Academia Sinica | Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains |
JP5918851B2 (ja) * | 2012-06-18 | 2016-05-18 | 日本全薬工業株式会社 | IgEペプチドワクチン |
US20150004161A1 (en) * | 2013-07-01 | 2015-01-01 | University Of Maryland | Fc Coupled Compositions and Methods of Their Use |
CN111741768A (zh) | 2017-10-31 | 2020-10-02 | 合一生技股份有限公司 | 治疗IgE介导的过敏性疾病 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8616166D0 (en) * | 1986-07-02 | 1986-08-06 | Research Corp Ltd | Polypeptide competitor |
GB8727045D0 (en) * | 1987-11-19 | 1987-12-23 | Research Corp Ltd | Immunoglobulin e competitor |
AU618317B2 (en) * | 1987-12-31 | 1991-12-19 | Tanox Biosystems, Inc. | Unique antigenic epitopes on ige-bearing b lymphocytes |
GB8910263D0 (en) * | 1989-05-04 | 1989-06-21 | Ciba Geigy Ag | Monoclonal antibodies specific for an immunoglobulin isotype |
GB8913737D0 (en) * | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
-
1991
- 1991-09-26 SE SE9102808A patent/SE9102808L/xx not_active Application Discontinuation
-
1992
- 1992-09-25 CA CA002117193A patent/CA2117193C/en not_active Expired - Fee Related
- 1992-09-25 RU RU94020409A patent/RU2120805C1/ru not_active IP Right Cessation
- 1992-09-25 DK DK92920757T patent/DK0666760T4/da active
- 1992-09-25 AU AU26765/92A patent/AU677573B2/en not_active Ceased
- 1992-09-25 HU HU9400845A patent/HU218899B/hu not_active IP Right Cessation
- 1992-09-25 AT AT92920757T patent/ATE189960T1/de not_active IP Right Cessation
- 1992-09-25 KR KR1019940700753A patent/KR100263359B1/ko not_active IP Right Cessation
- 1992-09-25 ES ES92920757T patent/ES2144424T5/es not_active Expired - Lifetime
- 1992-09-25 WO PCT/SE1992/000673 patent/WO1993005810A1/en active IP Right Grant
- 1992-09-25 US US08/196,227 patent/US5653980A/en not_active Expired - Lifetime
- 1992-09-25 JP JP50558293A patent/JP3583421B2/ja not_active Expired - Fee Related
- 1992-09-25 EP EP92920757A patent/EP0666760B2/en not_active Expired - Lifetime
- 1992-09-25 DE DE69230733T patent/DE69230733T3/de not_active Expired - Fee Related
-
1994
- 1994-03-14 FI FI941193A patent/FI107880B/fi active
-
2000
- 2000-04-19 GR GR20000400955T patent/GR3033272T3/el unknown
-
2004
- 2004-03-23 JP JP2004084530A patent/JP2004231663A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP3583421B2 (ja) | 2004-11-04 |
ES2144424T3 (es) | 2000-06-16 |
EP0666760A1 (en) | 1995-08-16 |
HU9400845D0 (en) | 1994-06-28 |
EP0666760B1 (en) | 2000-03-01 |
DE69230733T3 (de) | 2008-05-21 |
CA2117193C (en) | 2008-06-17 |
FI941193A (fi) | 1994-03-14 |
JPH06510768A (ja) | 1994-12-01 |
AU677573B2 (en) | 1997-05-01 |
DE69230733D1 (de) | 2000-04-06 |
HU218899B (hu) | 2000-12-28 |
AU2676592A (en) | 1993-04-27 |
ES2144424T5 (es) | 2008-03-01 |
SE9102808L (sv) | 1993-03-27 |
KR100263359B1 (ko) | 2000-08-01 |
JP2004231663A (ja) | 2004-08-19 |
US5653980A (en) | 1997-08-05 |
FI107880B (fi) | 2001-10-31 |
SE9102808D0 (sv) | 1991-09-26 |
CA2117193A1 (en) | 1993-04-01 |
RU2120805C1 (ru) | 1998-10-27 |
FI941193A0 (fi) | 1994-03-14 |
GR3033272T3 (en) | 2000-09-29 |
WO1993005810A1 (en) | 1993-04-01 |
DE69230733T2 (de) | 2000-08-03 |
HUT69782A (en) | 1995-09-28 |
DK0666760T3 (da) | 2000-07-31 |
EP0666760B2 (en) | 2007-10-10 |
ATE189960T1 (de) | 2000-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0666760T4 (da) | Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktioner | |
PT815235E (pt) | Vacinas para peste | |
ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
WO1996012794A3 (en) | Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity | |
ATE545652T1 (de) | Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien | |
CO5560581A2 (es) | Vacuna de epitopo de celula t beta-amiloide analogo | |
DK0643726T3 (da) | Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei | |
DE60040740D1 (de) | VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS | |
DK0482089T3 (da) | Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker | |
Magro et al. | Eosinophilic pustular follicular reaction: a paradigm of immune dysregulation | |
DK1021196T3 (da) | Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion | |
ES2319341T3 (es) | Fragmentos tolerogenicos de alergenos naturales. | |
DE69428272D1 (de) | Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum | |
FI971427A (fi) | Peptidit ja niitä sisältävät farmaseuttiset koostumukset | |
EP0958834A4 (en) | PEPTIDE IMMUNOTHERAPEUTIC ACTIVE | |
DE69330348D1 (de) | Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression. | |
ATE239502T1 (de) | Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten | |
DK0811067T3 (da) | Equin arteritisviruspeptider, antistoffer og deres anvendelse i en diagnostisk test | |
DK0959899T3 (da) | LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation | |
Ruben | Recombinant DNA produced human IL-2, injected in vivo, will substitute for carrier priming of helper function in the South African clawed toad, Xenopus laevis | |
DE60120391D1 (de) | Verwendung von hev-polypeptiden | |
CA2327631A1 (en) | Inflammatory cytokine secretion inhibition | |
Parkkonen | Virus-induced autoimmunity in the pathogenesis of type 1 diabetes. |